Health
DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19 – News-Medical.Net
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3…
RedHill Biopharma Ltd. (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.
Opaganib is a novel, orally-administered sphingosine…
-
Noosa News7 hours agoSES celebrates 50 years | Noosa Today
-
General12 hours agoGrieving parents of 4yo boy who drowned in Officer suing Melbourne Water, Cardinia council
-
Noosa News21 hours agoYummy Snack Foods pulled from shelves over labelling issue
-
Noosa News20 hours agoWhat are Medicare Mental Health Centres, and what do they offer?